Meeting
2023 ASCO Annual Meeting
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.
Authors
Hans Prenen
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
Hans Prenen , Ivan Borbath , Karen Paula Geboes , Philippe Alexandre Cassier , Aurélien Lambert , Emmanuel Mitry , Teresa Macarulla , Julien Taieb , Jean-Frédéric Blanc , Jaime Feliu Batlle , Mercedes Rodríguez Garrote , Roberto A. Pazo Cid , Manuel Valladares-Ayerbes , Karin Nordbladh , Karin Enell Smith , Peter Ellmark , Malin Carlsson , Yago Pico de Coaña , Sumeet Vijay Ambarkhane , Jean-Luc Van Laethem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04888312
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4139)
DOI
10.1200/JCO.2023.41.16_suppl.4139
Abstract #
4139
Poster Bd #
460
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2022 ASCO Annual Meeting
A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers